Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 14, 2012; 18(10): 1104-1109
Published online Mar 14, 2012. doi: 10.3748/wjg.v18.i10.1104
Published online Mar 14, 2012. doi: 10.3748/wjg.v18.i10.1104
Figure 1 Curves for the overall survival, and progression-free survival in patients with metastatic colorectal cancer after bevacizumab combined chemotherapy as a second- or later-line treatment.
A: Curves for the overall survival in patients with metastatic colorectal cancer after bevacizumab combined chemotherapy as a second- or later-line treatment; B: Curves for progression-free survival in patients with metastatic colorectal cancer after bevacizumab combined chemotherapy as a second- or later-line treatment.
- Citation: Park LC, Lee HS, Shin SH, Park SJ, Park MI, Oh SY, Kwon HC, Baek JH, Choi YJ, Kang MJ, Kim YS. Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer. World J Gastroenterol 2012; 18(10): 1104-1109
- URL: https://www.wjgnet.com/1007-9327/full/v18/i10/1104.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i10.1104